articleTop 1% cited

The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report

Journal of Clinical Oncology · 2008 · Vol. 27(2) · pp. 289–297

Susan L. Cohn✉(Children's Oncology Group)Andrew D.J. Pearson(Children's Oncology Group)Wendy B. London(Children's Oncology Group)Tom Monclair(Children's Oncology Group)Peter F. Ambros(Children's Oncology Group)Garrett M. Brodeur(Children's Oncology Group)Andreas Faldum(Children's Oncology Group)Barbara Hero(Children's Oncology Group)Tomoko Iehara(Children's Oncology Group)David Machin(Children's Oncology Group)Véronique Mosseri(Children's Oncology Group)Thorsten Simon(Children's Oncology Group)Alberto Garaventa(Children's Oncology Group)Victoria Castel(Children's Oncology Group)Katherine K. Matthay(Children's Oncology Group)

View via DOI Publisher page

Abstract

By defining homogenous pretreatment patient cohorts, the INRG classification system will greatly facilitate the comparison of risk-based clinical trials conducted in different regions of the world and the development of international collaborative studies.

Neuroblastoma Research and Treatments Adrenal and Paraganglionic Tumors Cancer, Hypoxia, and MetabolismMedicineNeuroblastomaInternal medicineOncologyCohortRisk stratification

MeSH terms

Age FactorsChild, PreschoolFerritinsHumansInfantL-Lactate DehydrogenaseNeoplasm MetastasisNeoplasm StagingNeuroblastomaRegression AnalysisRisk FactorsCohort StudiesInternational Classification of Diseases